Alcon has released its second-quarter 2024 financial results, reporting strong growth in its implantables and contact lenses segments. The company's revenue reached $2.48 billion, representing a 3.33% year-over-year increase, but fell short of Zack's estimate by 1.4%, missing expectations by $38 million. Despite the revenue miss, Alcon's earnings per share (EPS) of $0.74 marked a 7.25% increase from the previous year, exceeding estimates by $0.01. Surgical sales also saw a 3% increase, totaling $1.42 billion. However, the earnings miss led to a 2.6% drop in Alcon's share price in pre-market trading.